世界の慢性リンパ性白血病治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Chronic Lymphocytic Leukemia Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4012 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、慢性リンパ性白血病治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口薬、点滴薬、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・慢性リンパ性白血病治療薬の市場動向 ・企業の競争状況、市場シェア ・慢性リンパ性白血病治療薬の種類別市場規模と予測2016-2027（経口薬、点滴薬、その他） ・慢性リンパ性白血病治療薬の用途別市場規模と予測2016-2027（病院、診療所、その他） ・慢性リンパ性白血病治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・慢性リンパ性白血病治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・慢性リンパ性白血病治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・慢性リンパ性白血病治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・慢性リンパ性白血病治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AbbVie、AstraZeneca plc、Biogen Idec、Celgene Corporation、Cyclacel Pharmaceuticals、F. Hoffmann-La Roche AG、Genentech Inc、Genmab、Genzyme Corporation、Gilead Sciences、GlaxoSmithKline Plc、Infinity Pharmaceuticals、MorphoSys AG、Novartis AG、Noxxon Pharma AG、Teva Pharmaceutical Industries Ltd、TG Therapeutics） ・結論

Chronic Lymphocytic Leukemia (CLL) is a type of hematological malignancy marked by excessive proliferation of abnormal white blood cells. CLL predominantly affects the B-cell lymphocytes which are involved in the production of antibodies to fight against infections and foreign antigens. Rising incidence of CLL coupled with a high rate of mortality, demonstrates the unmet market need for better therapeutics.

Market Analysis and Insights: Global Chronic Lymphocytic Leukemia Drugs Market
The global Chronic Lymphocytic Leukemia Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chronic Lymphocytic Leukemia Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chronic Lymphocytic Leukemia Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chronic Lymphocytic Leukemia Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chronic Lymphocytic Leukemia Drugs market.

Global Chronic Lymphocytic Leukemia Drugs Scope and Market Size
Chronic Lymphocytic Leukemia Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Lymphocytic Leukemia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Oral Drugs
Intravenous Drugs
Others

Segment by Application
Hospital
Clinic
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie
AstraZeneca plc
Biogen Idec
Celgene Corporation
Cyclacel Pharmaceuticals
F. Hoffmann-La Roche AG
Genentech Inc
Genmab
Genzyme Corporation
Gilead Sciences
GlaxoSmithKline Plc
Infinity Pharmaceuticals
MorphoSys AG
Novartis AG
Noxxon Pharma AG
Teva Pharmaceutical Industries Ltd
TG Therapeutics

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Lymphocytic Leukemia Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral Drugs
1.2.3 Intravenous Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Chronic Lymphocytic Leukemia Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Chronic Lymphocytic Leukemia Drugs Market Perspective (2016-2027)
2.2 Chronic Lymphocytic Leukemia Drugs Growth Trends by Regions
2.2.1 Chronic Lymphocytic Leukemia Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Chronic Lymphocytic Leukemia Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Chronic Lymphocytic Leukemia Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Chronic Lymphocytic Leukemia Drugs Industry Dynamic
2.3.1 Chronic Lymphocytic Leukemia Drugs Market Trends
2.3.2 Chronic Lymphocytic Leukemia Drugs Market Drivers
2.3.3 Chronic Lymphocytic Leukemia Drugs Market Challenges
2.3.4 Chronic Lymphocytic Leukemia Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Chronic Lymphocytic Leukemia Drugs Players by Revenue
3.1.1 Global Top Chronic Lymphocytic Leukemia Drugs Players by Revenue (2016-2021)
3.1.2 Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Chronic Lymphocytic Leukemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chronic Lymphocytic Leukemia Drugs Revenue
3.4 Global Chronic Lymphocytic Leukemia Drugs Market Concentration Ratio
3.4.1 Global Chronic Lymphocytic Leukemia Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Lymphocytic Leukemia Drugs Revenue in 2020
3.5 Chronic Lymphocytic Leukemia Drugs Key Players Head office and Area Served
3.6 Key Players Chronic Lymphocytic Leukemia Drugs Product Solution and Service
3.7 Date of Enter into Chronic Lymphocytic Leukemia Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Chronic Lymphocytic Leukemia Drugs Breakdown Data by Type
4.1 Global Chronic Lymphocytic Leukemia Drugs Historic Market Size by Type (2016-2021)
4.2 Global Chronic Lymphocytic Leukemia Drugs Forecasted Market Size by Type (2022-2027)

5 Chronic Lymphocytic Leukemia Drugs Breakdown Data by Application
5.1 Global Chronic Lymphocytic Leukemia Drugs Historic Market Size by Application (2016-2021)
5.2 Global Chronic Lymphocytic Leukemia Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Chronic Lymphocytic Leukemia Drugs Market Size (2016-2027)
6.2 North America Chronic Lymphocytic Leukemia Drugs Market Size by Type
6.2.1 North America Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021)
6.2.2 North America Chronic Lymphocytic Leukemia Drugs Market Size by Type (2022-2027)
6.2.3 North America Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2027)
6.3 North America Chronic Lymphocytic Leukemia Drugs Market Size by Application
6.3.1 North America Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2021)
6.3.2 North America Chronic Lymphocytic Leukemia Drugs Market Size by Application (2022-2027)
6.3.3 North America Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2027)
6.4 North America Chronic Lymphocytic Leukemia Drugs Market Size by Country
6.4.1 North America Chronic Lymphocytic Leukemia Drugs Market Size by Country (2016-2021)
6.4.2 North America Chronic Lymphocytic Leukemia Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Chronic Lymphocytic Leukemia Drugs Market Size (2016-2027)
7.2 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Type
7.2.1 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021)
7.2.2 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Type (2022-2027)
7.2.3 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2027)
7.3 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Application
7.3.1 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2021)
7.3.2 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Application (2022-2027)
7.3.3 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2027)
7.4 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Country
7.4.1 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Country (2016-2021)
7.4.2 Europe Chronic Lymphocytic Leukemia Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size (2016-2027)
8.2 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Type
8.2.1 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Application
8.3.1 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Region
8.4.1 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Chronic Lymphocytic Leukemia Drugs Market Size (2016-2027)
9.2 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Type
9.2.1 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2027)
9.3 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Application
9.3.1 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2027)
9.4 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Country
9.4.1 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size (2016-2027)
10.2 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Type
10.2.1 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Application
10.3.1 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Country
10.4.1 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Chronic Lymphocytic Leukemia Drugs Introduction
11.1.4 AbbVie Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.1.5 AbbVie Recent Development
11.2 AstraZeneca plc
11.2.1 AstraZeneca plc Company Details
11.2.2 AstraZeneca plc Business Overview
11.2.3 AstraZeneca plc Chronic Lymphocytic Leukemia Drugs Introduction
11.2.4 AstraZeneca plc Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.2.5 AstraZeneca plc Recent Development
11.3 Biogen Idec
11.3.1 Biogen Idec Company Details
11.3.2 Biogen Idec Business Overview
11.3.3 Biogen Idec Chronic Lymphocytic Leukemia Drugs Introduction
11.3.4 Biogen Idec Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.3.5 Biogen Idec Recent Development
11.4 Celgene Corporation
11.4.1 Celgene Corporation Company Details
11.4.2 Celgene Corporation Business Overview
11.4.3 Celgene Corporation Chronic Lymphocytic Leukemia Drugs Introduction
11.4.4 Celgene Corporation Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.4.5 Celgene Corporation Recent Development
11.5 Cyclacel Pharmaceuticals
11.5.1 Cyclacel Pharmaceuticals Company Details
11.5.2 Cyclacel Pharmaceuticals Business Overview
11.5.3 Cyclacel Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Introduction
11.5.4 Cyclacel Pharmaceuticals Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.5.5 Cyclacel Pharmaceuticals Recent Development
11.6 F. Hoffmann-La Roche AG
11.6.1 F. Hoffmann-La Roche AG Company Details
11.6.2 F. Hoffmann-La Roche AG Business Overview
11.6.3 F. Hoffmann-La Roche AG Chronic Lymphocytic Leukemia Drugs Introduction
11.6.4 F. Hoffmann-La Roche AG Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.6.5 F. Hoffmann-La Roche AG Recent Development
11.7 Genentech Inc
11.7.1 Genentech Inc Company Details
11.7.2 Genentech Inc Business Overview
11.7.3 Genentech Inc Chronic Lymphocytic Leukemia Drugs Introduction
11.7.4 Genentech Inc Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.7.5 Genentech Inc Recent Development
11.8 Genmab
11.8.1 Genmab Company Details
11.8.2 Genmab Business Overview
11.8.3 Genmab Chronic Lymphocytic Leukemia Drugs Introduction
11.8.4 Genmab Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.8.5 Genmab Recent Development
11.9 Genzyme Corporation
11.9.1 Genzyme Corporation Company Details
11.9.2 Genzyme Corporation Business Overview
11.9.3 Genzyme Corporation Chronic Lymphocytic Leukemia Drugs Introduction
11.9.4 Genzyme Corporation Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.9.5 Genzyme Corporation Recent Development
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Details
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Chronic Lymphocytic Leukemia Drugs Introduction
11.10.4 Gilead Sciences Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.10.5 Gilead Sciences Recent Development
11.11 GlaxoSmithKline Plc
11.11.1 GlaxoSmithKline Plc Company Details
11.11.2 GlaxoSmithKline Plc Business Overview
11.11.3 GlaxoSmithKline Plc Chronic Lymphocytic Leukemia Drugs Introduction
11.11.4 GlaxoSmithKline Plc Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.11.5 GlaxoSmithKline Plc Recent Development
11.12 Infinity Pharmaceuticals
11.12.1 Infinity Pharmaceuticals Company Details
11.12.2 Infinity Pharmaceuticals Business Overview
11.12.3 Infinity Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Introduction
11.12.4 Infinity Pharmaceuticals Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.12.5 Infinity Pharmaceuticals Recent Development
11.13 MorphoSys AG
11.13.1 MorphoSys AG Company Details
11.13.2 MorphoSys AG Business Overview
11.13.3 MorphoSys AG Chronic Lymphocytic Leukemia Drugs Introduction
11.13.4 MorphoSys AG Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.13.5 MorphoSys AG Recent Development
11.14 Novartis AG
11.14.1 Novartis AG Company Details
11.14.2 Novartis AG Business Overview
11.14.3 Novartis AG Chronic Lymphocytic Leukemia Drugs Introduction
11.14.4 Novartis AG Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.14.5 Novartis AG Recent Development
11.15 Noxxon Pharma AG
11.15.1 Noxxon Pharma AG Company Details
11.15.2 Noxxon Pharma AG Business Overview
11.15.3 Noxxon Pharma AG Chronic Lymphocytic Leukemia Drugs Introduction
11.15.4 Noxxon Pharma AG Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.15.5 Noxxon Pharma AG Recent Development
11.16 Teva Pharmaceutical Industries Ltd
11.16.1 Teva Pharmaceutical Industries Ltd Company Details
11.16.2 Teva Pharmaceutical Industries Ltd Business Overview
11.16.3 Teva Pharmaceutical Industries Ltd Chronic Lymphocytic Leukemia Drugs Introduction
11.16.4 Teva Pharmaceutical Industries Ltd Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.16.5 Teva Pharmaceutical Industries Ltd Recent Development
11.17 TG Therapeutics
11.17.1 TG Therapeutics Company Details
11.17.2 TG Therapeutics Business Overview
11.17.3 TG Therapeutics Chronic Lymphocytic Leukemia Drugs Introduction
11.17.4 TG Therapeutics Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
11.17.5 TG Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Chronic Lymphocytic Leukemia Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oral Drugs
Table 3. Key Players of Intravenous Drugs
Table 4. Key Players of Others
Table 5. Global Chronic Lymphocytic Leukemia Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Chronic Lymphocytic Leukemia Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Chronic Lymphocytic Leukemia Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Chronic Lymphocytic Leukemia Drugs Market Share by Regions (2016-2021)
Table 9. Global Chronic Lymphocytic Leukemia Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Chronic Lymphocytic Leukemia Drugs Market Share by Regions (2022-2027)
Table 11. Chronic Lymphocytic Leukemia Drugs Market Trends
Table 12. Chronic Lymphocytic Leukemia Drugs Market Drivers
Table 13. Chronic Lymphocytic Leukemia Drugs Market Challenges
Table 14. Chronic Lymphocytic Leukemia Drugs Market Restraints
Table 15. Global Chronic Lymphocytic Leukemia Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Chronic Lymphocytic Leukemia Drugs Market Share by Players (2016-2021)
Table 17. Global Top Chronic Lymphocytic Leukemia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Lymphocytic Leukemia Drugs as of 2020)
Table 18. Ranking of Global Top Chronic Lymphocytic Leukemia Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Chronic Lymphocytic Leukemia Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Chronic Lymphocytic Leukemia Drugs Product Solution and Service
Table 22. Date of Enter into Chronic Lymphocytic Leukemia Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global Chronic Lymphocytic Leukemia Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Chronic Lymphocytic Leukemia Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share by Application (2016-2021)
Table 30. Global Chronic Lymphocytic Leukemia Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Chronic Lymphocytic Leukemia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Chronic Lymphocytic Leukemia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Chronic Lymphocytic Leukemia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Chronic Lymphocytic Leukemia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Chronic Lymphocytic Leukemia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Chronic Lymphocytic Leukemia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Chronic Lymphocytic Leukemia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Chronic Lymphocytic Leukemia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Chronic Lymphocytic Leukemia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. AbbVie Company Details
Table 63. AbbVie Business Overview
Table 64. AbbVie Chronic Lymphocytic Leukemia Drugs Product
Table 65. AbbVie Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 66. AbbVie Recent Development
Table 67. AstraZeneca plc Company Details
Table 68. AstraZeneca plc Business Overview
Table 69. AstraZeneca plc Chronic Lymphocytic Leukemia Drugs Product
Table 70. AstraZeneca plc Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 71. AstraZeneca plc Recent Development
Table 72. Biogen Idec Company Details
Table 73. Biogen Idec Business Overview
Table 74. Biogen Idec Chronic Lymphocytic Leukemia Drugs Product
Table 75. Biogen Idec Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 76. Biogen Idec Recent Development
Table 77. Celgene Corporation Company Details
Table 78. Celgene Corporation Business Overview
Table 79. Celgene Corporation Chronic Lymphocytic Leukemia Drugs Product
Table 80. Celgene Corporation Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 81. Celgene Corporation Recent Development
Table 82. Cyclacel Pharmaceuticals Company Details
Table 83. Cyclacel Pharmaceuticals Business Overview
Table 84. Cyclacel Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Product
Table 85. Cyclacel Pharmaceuticals Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 86. Cyclacel Pharmaceuticals Recent Development
Table 87. F. Hoffmann-La Roche AG Company Details
Table 88. F. Hoffmann-La Roche AG Business Overview
Table 89. F. Hoffmann-La Roche AG Chronic Lymphocytic Leukemia Drugs Product
Table 90. F. Hoffmann-La Roche AG Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 91. F. Hoffmann-La Roche AG Recent Development
Table 92. Genentech Inc Company Details
Table 93. Genentech Inc Business Overview
Table 94. Genentech Inc Chronic Lymphocytic Leukemia Drugs Product
Table 95. Genentech Inc Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 96. Genentech Inc Recent Development
Table 97. Genmab Company Details
Table 98. Genmab Business Overview
Table 99. Genmab Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 100. Genmab Recent Development
Table 101. Genzyme Corporation Company Details
Table 102. Genzyme Corporation Business Overview
Table 103. Genzyme Corporation Chronic Lymphocytic Leukemia Drugs Product
Table 104. Genzyme Corporation Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 105. Genzyme Corporation Recent Development
Table 106. Gilead Sciences Company Details
Table 107. Gilead Sciences Business Overview
Table 108. Gilead Sciences Chronic Lymphocytic Leukemia Drugs Product
Table 109. Gilead Sciences Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 110. Gilead Sciences Recent Development
Table 111. GlaxoSmithKline Plc Company Details
Table 112. GlaxoSmithKline Plc Business Overview
Table 113. GlaxoSmithKline Plc Chronic Lymphocytic Leukemia Drugs Product
Table 114. GlaxoSmithKline Plc Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 115. GlaxoSmithKline Plc Recent Development
Table 116. Infinity Pharmaceuticals Company Details
Table 117. Infinity Pharmaceuticals Business Overview
Table 118. Infinity Pharmaceuticals Chronic Lymphocytic Leukemia Drugs Product
Table 119. Infinity Pharmaceuticals Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 120. Infinity Pharmaceuticals Recent Development
Table 121. MorphoSys AG Company Details
Table 122. MorphoSys AG Business Overview
Table 123. MorphoSys AG Chronic Lymphocytic Leukemia Drugs Product
Table 124. MorphoSys AG Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 125. MorphoSys AG Recent Development
Table 126. Novartis AG Company Details
Table 127. Novartis AG Business Overview
Table 128. Novartis AG Chronic Lymphocytic Leukemia Drugs Product
Table 129. Novartis AG Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 130. Novartis AG Recent Development
Table 131. Noxxon Pharma AG Company Details
Table 132. Noxxon Pharma AG Business Overview
Table 133. Noxxon Pharma AG Chronic Lymphocytic Leukemia Drugs Product
Table 134. Noxxon Pharma AG Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 135. Noxxon Pharma AG Recent Development
Table 136. Teva Pharmaceutical Industries Ltd Company Details
Table 137. Teva Pharmaceutical Industries Ltd Business Overview
Table 138. Teva Pharmaceutical Industries Ltd Chronic Lymphocytic Leukemia Drugs Product
Table 139. Teva Pharmaceutical Industries Ltd Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 140. Teva Pharmaceutical Industries Ltd Recent Development
Table 141. TG Therapeutics Company Details
Table 142. TG Therapeutics Business Overview
Table 143. TG Therapeutics Chronic Lymphocytic Leukemia Drugs Product
Table 144. TG Therapeutics Revenue in Chronic Lymphocytic Leukemia Drugs Business (2016-2021) & (US$ Million)
Table 145. TG Therapeutics Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Lymphocytic Leukemia Drugs Market Share by Type: 2020 VS 2027
Figure 2. Oral Drugs Features
Figure 3. Intravenous Drugs Features
Figure 4. Others Features
Figure 5. Global Chronic Lymphocytic Leukemia Drugs Market Share by Application: 2020 VS 2027
Figure 6. Hospital Case Studies
Figure 7. Clinic Case Studies
Figure 8. Others Case Studies
Figure 9. Chronic Lymphocytic Leukemia Drugs Report Years Considered
Figure 10. Global Chronic Lymphocytic Leukemia Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Chronic Lymphocytic Leukemia Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Chronic Lymphocytic Leukemia Drugs Market Share by Regions: 2020 VS 2027
Figure 13. Global Chronic Lymphocytic Leukemia Drugs Market Share by Regions (2022-2027)
Figure 14. Global Chronic Lymphocytic Leukemia Drugs Market Share by Players in 2020
Figure 15. Global Top Chronic Lymphocytic Leukemia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Lymphocytic Leukemia Drugs as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Chronic Lymphocytic Leukemia Drugs Revenue in 2020
Figure 17. Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share by Type (2016-2021)
Figure 18. Global Chronic Lymphocytic Leukemia Drugs Revenue Market Share by Type (2022-2027)
Figure 19. North America Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Chronic Lymphocytic Leukemia Drugs Market Share by Type (2016-2027)
Figure 21. North America Chronic Lymphocytic Leukemia Drugs Market Share by Application (2016-2027)
Figure 22. North America Chronic Lymphocytic Leukemia Drugs Market Share by Country (2016-2027)
Figure 23. United States Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Chronic Lymphocytic Leukemia Drugs Market Share by Type (2016-2027)
Figure 27. Europe Chronic Lymphocytic Leukemia Drugs Market Share by Application (2016-2027)
Figure 28. Europe Chronic Lymphocytic Leukemia Drugs Market Share by Country (2016-2027)
Figure 29. Germany Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Chronic Lymphocytic Leukemia Drugs Market Share by Region (2016-2027)
Figure 39. China Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Chronic Lymphocytic Leukemia Drugs Market Share by Type (2016-2027)
Figure 47. Latin America Chronic Lymphocytic Leukemia Drugs Market Share by Application (2016-2027)
Figure 48. Latin America Chronic Lymphocytic Leukemia Drugs Market Share by Country (2016-2027)
Figure 49. Mexico Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Chronic Lymphocytic Leukemia Drugs Market Share by Country (2016-2027)
Figure 55. Turkey Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Chronic Lymphocytic Leukemia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. AbbVie Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 59. AstraZeneca plc Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 60. Biogen Idec Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 61. Celgene Corporation Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 62. Cyclacel Pharmaceuticals Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 63. F. Hoffmann-La Roche AG Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 64. Genentech Inc Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 65. Genmab Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 66. Genzyme Corporation Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 67. Gilead Sciences Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 68. GlaxoSmithKline Plc Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 69. Infinity Pharmaceuticals Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 70. MorphoSys AG Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 71. Novartis AG Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 72. Noxxon Pharma AG Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 73. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 74. TG Therapeutics Revenue Growth Rate in Chronic Lymphocytic Leukemia Drugs Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed

---